Orally active inhibitor of the Notch signaling activation complex (IC50s from 0.9 to 3.9 µM in various cell-based assays), the most downstream level of the Notch signaling pathway. It inhibited the growth of Notch-addicted human T cell acute lymphoblastic leukemia cells as well as other cell lines. CB-103 also inhibited the growth of human breast cancer and leukemia xenografts without the intestinal toxicity associated with gamma-secretase Notch inhibitors.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten